A Randomized, Placebo-Controlled Trial of HPV Vaccination to Reduce Cervical High-Grade Squamous Intraepithelial Lesions Among HIV-Infected Women Participating in an HPV Test-and-Treat Program (COVENANT)
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
- Indications Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms COVENANT
- 31 Jul 2019 Planned End Date changed from 1 Apr 2022 to 1 Jan 2023.
- 31 Jul 2019 Planned primary completion date changed from 1 Apr 2021 to 1 Jan 2022.
- 31 Jul 2019 Status changed from not yet recruiting to recruiting.